• ABOTA defends Judge Gilstrap in response to political pressure from Darrell Issa

    Issa decried Judge Gilstrap’s “overreach” in denying a motion to transfer venue in a case coming after the U.S. Supreme Court’s decision in TC Heartland LLC v. Kraft Foods Group Brands LLC, a decision which restricted the venue statute for patent infringement cases. “It is, in fact, an act that I find reprehensible by that judge,” Issa said… American Board of Trial Advocates (ABOTA) noted that Issa’s further assertion that Judge Gilstrap was motivated by personal bias to promote community…

    Continue Reading ...
  • Ensuring a robust defensive portfolio: A Prepared Counter-Assertion Strategy

    The required number of patents in a given playbook varies based on both the size of company of concern and our exposure to it. The general goal of a playbook is to shift the licensing amount purportedly owed by LinkedIn by $20 million to $200 million in our favor. In order to achieve this, we have found that a good playbook should contain between three and 10 patent families, with evidence of use for key patents. The goal of each playbook is to show infringement by the asserter’s products and…

    Continue Reading ...
  • Evolution of Gas Sensors: Beatrice Hicks creates device to measure gas in critical industrial applications

    Inventor, Beatrice Hicks, is both a 2017 inductee into the National Inventors Hall of Fame as well as one of America’s truly trailblazing women engineers, one of the first to enter the field of technological development in the mid-20th century. Hicks would go on to become instrumental in the founding of the Society of Women Engineers and her story is a wonderful reminder of the power of both a good education and the ability to believe in one’s self… Hicks’ major innovation in gas sensor tech…

    Continue Reading ...
  • Conference & CLE Calendar

    July 24-25, 2017 – TTS North America summit*** (TTS Ltd.) – Weill Cornell Medicine in New York, NY July 25-26, 2017 – “Advanced Patent Prosecution Workshop 2017: Claim Drafting & Amendment Writing” (Practising Law Institute) – New York, NY July 27,…

    Continue Reading ...
  • COMPEL

                            目次はこちら

    COMPEL

    $$ The bottom end of the shock strut (coupled to the wheel assembly) will be compelled to follow a path dictated by its attachment point to the elon…

    Continue Reading ...
  • CBS Sunday Morning on 23 July 2017 repeats work on immunotherapy treatments for cancer

    On July 23, 2017, CBS Sunday Morning repeated a March 12 broadcast on cancer wherein CBS New chief medical correspondent Dr.Jon LaPook (not Jane Pauley) hosted a special edition of CBS Sunday Morning, devoted to cancer research and treatment. The Beyond Cancer edition featured Dr. LaPook’s report on the promising field of immunotherapy, in turn featuring work of Dr. Steven Rosenberg of NIH/NCI. Other portions included Rita Braver‘s interview with singer-songwriter and breast cancer survivor Sheryl Crow and Erin Moriarty on women who decided to forego breast reconstruction surgery following a double mastectomy

    Note an August 2016 post
    USPTO Offers a Fast Track to Cancer Immunotherapy Patents

    AND from MoFo on 23 June 2017:


    The United States Patent and Trademark Office (PTO) issued a Notice today extending the Cancer Immunotherapy Pilot
    Program (Pilot Program), also known as “Patents 4 Patients.” The Pilot Program, which accelerates the examination of
    patent applications directed to cancer immunotherapy methods, will now expire on December 31, 2018, absent further
    extension.
    The PTO implemented the Pilot Program a year ago as part of the National Cancer Moonshot initiative. That initiative seeks
    to transform cancer research and care by substantially accelerating efforts to combat cancer over the next five years.
    Because the patent system is a driver of innovation, the program aims to advance cancer treatments so that they may
    reach patients faster. Specifically, the Pilot Program seeks to achieve allowance of meritorious patents within 12 months
    from filing a petition under the program.
    There were more than 900 immunotherapy patent applications pending when the Pilot Program was first implemented. That
    number likely has grown substantially due to the innovations in the immuno-oncology field. In its Notice, the PTO indicated
    that 80 petitions have been requested, to date, and nine eligible patents have been granted under the Pilot Program.

    Continue Reading ...